Lenabasum is under clinical development by Corbus Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Lenabasum’s likelihood of approval (LoA) and phase transition for Systemic Lupus Erythematosus took place on 05 Dec 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Lenabasum Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Lenabasum is under development for the treatment of systemic lupus erythematosus, diffuse cutaneous systemic sclerosis. It is an oral endo cannabinoid mimetic. The drug candidate acts by targeting cannabinoid receptor 2 (CB2). JBT-101 a nanomolar cannabinoid and is based on the core structure of Tetrahydrocannabinol (THC). It was under development for the treatment of bladder pain, inflammatory disorders and bladder overactivity in hypersensitive bladder disorders such as interstitial cystitis, cystic fibrosis, skin-predominant dermatomyositis and neuropathic pain. It is a new chemical entity (NCE).
Corbus Pharmaceuticals overview
Corbus Pharmaceuticals a subsidiary company of Corbus Pharmaceuticals Holdings Inc is engaged in the manufacture of f novel therapeutics to treat inflammatory and fibrotic diseases. The company is headquartered in the US.
Quick View Lenabasum LOA Data
|Highest Development Stage|